KBC Group
KROS icon

KBC Group’s Keros Therapeutics KROS Stock Holding History

KBC Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,622
Closed -$26K – 1887
2024
Q4 		$26K Buy
1,622
+359
+28% +$18.7K ﹤0.01% 1828
2024
Q3 		$73K Buy
1,263
+432
+52% +$21.3K ﹤0.01% 1494
2024
Q2 		$38K Buy
831
+65
+8% +$3.49K ﹤0.01% 1745
2024
Q1 		$51K Buy
+766
New +$45.4K ﹤0.01% 1547

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KBC Group's KROS Position: Q1 2025 in Review

KBC Group sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 1,622 shares — an estimated $26K sold.

KBC Group first reported a position in KROS in Q1 2024 and held it in 4 quarters. The position peaked at $73K in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • KBC Group reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • KBC Group sold 1,622 Keros Therapeutics shares in Q1 2025, an estimated $26K.
  • KBC Group first reported a position in Keros Therapeutics in Q1 2024 and held it in 4 quarters.
  • KBC Group's Keros Therapeutics position peaked at $73K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on KBC Group's 13F filing for Q1 2025, filed 25 Apr 2025.